Published • loading... • Updated
Roche’s Obesity Drug Boosts Blood Sugar Control, Drives 15.5% Weight Loss in Mid-Stage Trial
8 Articles
8 Articles
Roche’s obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Sept 22 (Reuters) - Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial...
The Swiss pharmaceutical industry's goal is to achieve third place in the market.
The Swiss pharmaceutical company is starting to compete with Eli Lilly and Novo Nordisk in a $150 billion annual market.
Swiss pharmaceutical giant Roche has passed a trial of its first weight-loss drug, which the company hopes will take on Novo and Eli Lilly within a few years.
Coverage Details
Total News Sources8
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
